PerkinElmer buying antibody maker for $5.25B

PerkinElmer is buying antibody and reagents maker BioLegend in a $5.25 billion deal, the companies said July 26. 

The transaction, expected to close by the end of 2021, is the largest in PerkinElmer's history. 

Under the deal, BioLegend's San Diego campus will become PerkinElmer's global center of excellence for research reagent content development. 

BioLegend has estimated 2022 revenue of $380 million. 

Read the full news release here

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars